Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | CES2 | O00748 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079803 | 1.00 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL27702807 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL29282556 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL11409155 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL28399012 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL28861274 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL11614678 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL29129734 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL28733182 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 | |
| SCHEMBL10875037 | 0.97 | CYP3A4 (0.63) | CYP3A4TDP1ESR1ESR2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112010744-A | Farnesyl acetone and preparation method thereof | 武汉臻智生物科技有限公司 | 2020-12-01 | — | — | CN | claimed |
| CN-112010744-A | Farnesyl acetone and preparation method thereof | 武汉臻智生物科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
| US-7759373-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1432690-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| WO-2002083111-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-24 | — | — | WO | disclosed |
| US-4193942-A | METAL COMPLEX CONTAINING COBALT, RHODIUM, RUTHENIUM, OR IRIDIUM AND A PHOSPHITE OR PHOSPHINE IN A LIGAND-FORMING SOLVENT | STAMICARBON, B.V. (NL) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | KCNN3, KCNN2, KCNN1 | CYP3A4 1918/4885TDP1 4798/4885ESR1 2012/4885 |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | KCNN1, KCNN4, KCNN3 | CYP3A4 1069/4885TDP1 4797/4885ESR1 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.